Research programme: utrophin modulators - Summit / University of Oxford

Drug Profile

Research programme: utrophin modulators - Summit / University of Oxford

Alternative Names: SMT 022357

Latest Information Update: 07 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Oxford
  • Developer Summit Therapeutics; University of Oxford
  • Class Small molecules
  • Mechanism of Action Utrophin modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Duchenne muscular dystrophy

Most Recent Events

  • 04 Oct 2016 Summit Therapeutics and Sarepta Therapeutics agree to co-develop utrophin modulators in Turkey, Common Wealth of Independent States and Europe for Duchenne muscular dystrophy
  • 17 Nov 2015 Summit Therapeutics extends its collaboration with University of Oxford for development of utrophin modulators for Duchenne muscular dystrophy
  • 30 Sep 2015 Pharmacodynamics data from preclinical study in Duchenne muscular dystrophy released by Summit Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top